

PLOS ONE

1 High prevalence and risk factors of transmission of hepatitis delta virus in 2 pregnant women in the Center Region of Cameroon

3
4 Juliette-Laure Ndzie Ondigui^{1,2}, Email : njulielaure@gmail.com

5 Nadège Mafopa Goumkwa², Email : g.m.nadege@gmail.com

6 Cindy Lobe^{2,3}, Email: lobecindy@hotmail.com

7 Brigitte Wandji⁴, Email: wandji.brigitte@yahoo.com

8 Patrick Awoumou^{5,2}, Email: patrick26lebon@gmail.com

9 Prisca Voussou Djivida⁵, Email : djividaprisca@yahoo.fr

10 Puinta Peyonga⁵, Email : puipen@yahoo.com

11 Solange Manju Atah⁶ Email : solangeneh36@gmail.com

12 Vivian Verbe⁷, Email : visale@yahoo.com

13 Rachel Kamgaing Simo², Email: r.kamgaing@yahoo.it

14 Sylvie Agnès Moudourou², Email : sylvie.moudourou@gmail.com

15 Ana Gutierrez⁹, Email : anagutiaci@yahoo.es

16 Rosi Garcia⁹, Email : rosi.acibikop@gmail.com

17 Isabelle Fernandez⁹, Email : i.fernandez@esclavasaci.es

18 Sara Honorine Riwoom Essama¹, Email : sarariwom@yahoo.fr

19 Robinson Mbu^{4,10}, Email : robinsonmbu@gmail.com

20 Judith Torimiro^{2, 5*}, Email: jn.torimiro@gmail.com

21

22 *1-Department of Microbiology, Faculty of Sciences, University of Yaoundé 1, Yaounde,*
23 *Cameroon;*

24 *2- “Chantal BIYA” International Reference Center for research on HIV/AIDS prevention and*
25 *management (CIRCB), Yaounde, Cameroon;*

26 *3- Department of Food Science and Nutrition, National School of Agro-Industrial Sciences,*
27 *University of Ngaoundere, Ngaoundere, Cameroon;*

28 *4- Yaoundé Gynecology Obstetrics and Paediatrics Hospital, Yaounde, Cameroon;*

29 *5- Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of*
30 *Yaounde 1, Yaounde, Cameroon;*

31 *6- Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of*
32 *Yaounde 1, Yaounde, Cameroon;*

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

PLOS ONE

33 7-Cité Verte District Hospital, Yaounde, Cameroon;

34 8- Biyem-Assi District Hospital, Yaounde, Cameroon

35 9- Bikop Catholic Health Center, Bikop, Cameroon

36 10- Department of Gynecology/Obstetrics, Faculty of Medicine and Biomedical Sciences,

37 University of Yaounde 1, Yaounde, Cameroon

38 **Authors Contributions**

39 *Designed the study:* Judith Torimiro, Robinson Mbu, Sara Honorine Riwom Essama, Juliette-

40 Laure Ndzie Ondigui; *Collected the data:* Judith Torimiro, Juliette-Laure Ndzie Ondigui,

41 Brigitte Wandji, Patrick Awoumou, Puinta Peyong, Prisca Voussou Djivida, Vivian Verbe,

42 Eveline Tincho Fogueu, Rachel Kamgaing Simo, Sylvie Agnès Moudourou , Ana Gutierrez ,

43 Rosi Garcia, Isabelle Fernandez; *Analyzed and interpreted the data:* Juliette-Laure Ndzie

44 Ondigui, Nadège Mafopa Goumkwa, Cindy Lobe, Judith Torimiro; *Initiated and drafted the*

45 *manuscript:* Juliette-Laure Ndzie Ondigui, Nadège Mafopa Goumkwa, Judith Torimiro;

46 *Revised the manuscript:* all the authors read and approved the final manuscript.

47 ***Corresponding author:**

48 Judith Torimiro

49 Email: jn.torimiro@gmail.com

50

51

52

53

54

55

56

57

58

59

60

61

62

63

PLOS ONE

64 ABSTRACT

65 **Background:** Hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection has been
66 described as the most severe form of viral hepatitis, and both can be co-transmitted from
67 mother-to-child. A seroprevalence of 4.0% of HDV infection was reported in pregnant women
68 in Yaoundé, and 11.9% in the general population in Cameroon. Our objective was to describe
69 the rate of HDV infection in pregnant women and to determine risk factors associated with
70 mother-to-child transmission of HDV.

71 **Materials and Methods:** A cross-sectional, descriptive study was conducted from January
72 2019 to July 2022 among pregnant women attending antenatal contacts in seven health
73 structures in the Centre Region of Cameroon. A consecutive sampling (non-probability
74 sampling) was used to select only women of age over 21 years, who gave a written informed
75 consent. Following an informed consent, an open-ended questionnaire was used for a
76 Knowledge, Attitude and Practice (KAP) survey of these women, and their blood specimens
77 collected and were screened for HBsAg, anti-HIV and anti-HCV antibodies by rapid tests and
78 ELISA. HBsAg-positive samples were further screened for HBeAg, anti-HDV, anti-HBs, and
79 anti HBc antibodies by ELISA, and plasma HDV RNA load measured by RT-qPCR.

80 **Results:** Of 1992 pregnant women, a rate of 6.7% of HBsAg (134/1992) with highest rate in
81 the rural areas, and 3.9% of hepatitis vaccination rate were recorded. Of 134, 44 (32.3%) were
82 anti-HDV antibody-positive, and 47.6% had detectable RNA viraemia. Two women of 44 anti-
83 HDV-positive cases (4.5%) were co-infected with HBV and HCV, while 5 (11.4%) with HIV
84 and HBV. Multiple deliveries, the presence of tattoos and/or scarifications were significantly
85 statistically associated with the presence of anti-HDV antibodies. Of note, 80% of women with
86 negative HBeAg and positive anti-HBe serological profile, had plasma HDV RNA load of more
87 than log 3.25 (>10.000 copies/ml).

88 Conclusion

89 These results show an intermediate rate of HDV infection among pregnant women with high
90 level of HDV RNA viremia, which suggest an increased risk of vertical and horizontal co-
91 transmission of HDV.

92

93 **Keywords:** risk factors, transmission, hepatitis delta virus, pregnancy

PLOS ONE

94 **Introduction**

95 Hepatitis B virus (HBV) is the aetiologic agent of hepatitis B. The WHO estimates that 296
96 million people were living with chronic hepatitis B in 2019 with 1.5 million new infections
97 each year[1], whereas Hepatitis delta virus (HDV) affects nearly 5% of people with chronic
98 hepatitis B worldwide[1]. HDV requires the presence of HBV in order to replicate [2-4] in co-
99 infection or super-infection causing the most serious form of chronic viral hepatitis, given its
100 more rapid progression to hepatocellular carcinoma and death [5-8]. It is also worth noting, the
101 low HBV vaccination rate among pregnant women in Cameroon of less than 2.5% [9].

102 HBV and HDV can be transmitted through skin lesions (injection, scarification, tattooing),
103 contact with infected blood or blood products, but mostly they are co-transmitted through sexual
104 intercourse and from mother-to-child [10]. Therefore, pregnant women are an index population
105 for both vertical and horizontal transmission of HBV and HDV. However, certain practices
106 favour the transmission of HBV in the Centre Region of Cameroon. They include poor
107 accessibility to healthcare, low rate of vaccination, cultural and traditional beliefs, low rate of
108 condom use, high rate of early age of first sexual intercourse, low rate of official marriage, high
109 rate of home delivery, poor link to prevention of mother-to-child transmission (PMTCT)
110 activities, and to other maternal-infant disease prevention efforts in Cameroon.

111 HBV/HDV co-transmission from mother-to-child has been described [11, 12]. It is an event
112 that seems rare but remains possible and the risk could increase with high level of plasma load
113 of HBV DNA and HDV RNA in the pregnant woman [13-15], in individuals with multiple
114 sexual partners and/or with scarification [16]. Vaccination against hepatitis B is an effective
115 strategy to prevent HDV infection. Therefore, scaling-up the national vaccination programme
116 against hepatitis B in the general population, could lead to a drop in the incidence of hepatitis
117 D worldwide. In 2018, it was reported that 83.3% of pregnant women attending ANC in
118 Yaounde, Cameroon, knew that vaccination against HBV infection is a method of prevention,
119 and 47.1% knew that HBV could be transmitted from mother-to-child. However, only 2.5%
120 had received three doses of the hepatitis B vaccine [9, 17]. In Cameroon the seroprevalence of
121 HBV (HBsAg) in the general population is 11.2%, about two to three times higher than that of
122 the human immunodeficiency virus (HIV) of 3.4% [18, 19]. In 2021, the Cameroon Ministry
123 of Public Health reported a seroprevalence among pregnant women at first trimester of 5.0% in
124 the Centre Region where this study was carried out against 8.63% of national prevalence [20].
125 In addition, in Central Africa, HDV seroprevalence is estimated at 25.64% in the general
126 population [7], compared to 46.73% in Cameroon in 2018 [21].

PLOS ONE

127 Low hepatitis B vaccination coverage in the sexually active population, and lack of recent
128 epidemiological data on HDV in pregnant women, show that the general population in
129 Cameroon is at risk of continuous spread of HBV and HDV from mother-to-child and
130 horizontally. Thus, our specific objectives were to determine the rates of HDV infection and
131 factors associated with risk of HDV infection among pregnant women.

132 **Materials and methods**

133 **Study design, enrollment procedure and eligibility criteria**

134 A cross-sectional study was conducted from January 2019 to July 2022 in a tertiary hospital,
135 five District hospitals, and one rural Health Center in the Center Region of Cameroon, among
136 pregnant women attending ANC. A total of 1992 pregnant women of age over 21 years were
137 enrolled (Figure 1) from an anticipated 1475 participants deduced from a statistical formula
138 shown below [22] which is commonly used to determine the minimum sample size in medical
139 studies:

$$140 \quad n = (Z\alpha)^2 p (1 - p) / d^2$$

141 where:

142 $Z\alpha$ = standard normal variate (1.96 for a 95% confidence interval);

143 p = prevalence of HDV among pregnant women in Cameroon (4.0) [9];

144 d = precision of the estimate (0.01).

145 Substituting the figures in the above formula yields 1475.2 (nearest whole number). Thus, a
146 minimum of 1475 participants was required.

147 Data collection took place in 3 stages. Before enrolling the participants, a group sensitization
148 at the hospital or Health Center was conducted to raise awareness on hepatitis B transmission
149 and prevention, hepatitis B and pregnancy, the importance of HBV screening and the purpose
150 of the study. Thereafter, 1992 subjects who were willing to be part of the study, were
151 administered a Consent Form, and upon their consent, a questionnaire with open-ended
152 questions was administered to collect personal and socio-demographic data, their knowledge,
153 attitude and practices with respect to hepatitis B. Some women who took part in the sensitization
154 campaign were not enrolled in the study because they had to have the opinion of their partners,
155 or did not give any reason.

PLOS ONE

156 A consecutive sampling (non-probability sampling) was used to select only pregnant women of
157 age over 21 years, who gave a written informed consent. In order to avoid any confusion and
158 to preserve the anonymity of the participants, each participant was assigned a code that allowed
159 us to link each questionnaire to its corresponding blood specimen, while another Register of the
160 ANC used only by hospital staff was established to link the subjects to their results. This same
161 code was used throughout the analysis in the laboratory and the results were linked to the
162 identity of the subject by the hospital staff and not by the research team.

163 **Laboratory procedures**

164 After completing the questionnaire, 5 ml of blood was drawn from 1992 subjects into a tube
165 containing ethylene-diamine-tetra-acetic acid (EDTA), processed and the plasma tested for
166 HBsAg, anti-HIV and anti-HCV antibodies using rapid diagnostic tests (RDT, ABON,
167 Determine HIV1/2 and KHB Diagnostic kit for HIV antibodies 1 + 2) and ELISA (Murex
168 HBsAg, and Murex HCV Ab), following the manufacturer's instructions. Furthermore, the
169 HBsAg-positive samples were tested by ELISA for other HBV infection biomarkers: anti-HBs,
170 anti-HBc, HBeAg, and anti-HBe. Positive and negative plasma controls were run alongside
171 each test, following the National Testing Algorithms for these viruses in Cameroon.

172 ELISA was performed to detect anti-HDV antibodies in 134 plasma samples using the ETI-
173 DELTA-IGMK-2 kit (Dia.Pro Diagnostic Bioprobes srl, Italy). Quantification of HDV RNA
174 (viral RNA load) by real-time qRT-PCR (Eurobioplex HDV Kit, Eurobio Scientific, France)
175 was performed using 34 anti-HDV positive plasma samples. All serologic results were made
176 available to the women within two weeks after specimen collection. The rapid test results were
177 confirmed by two technicians and the samples with borderline results, were further analyzed by
178 ELISA. On the other hand, plasma HDV RNA load was quantified by qRT-PCR commercial kit that
179 detects all 8 main genotypes of HDV, with a lower limit of detection of 100IU/mL. Through these
180 analyses, the subjects that were infected with HBV and/or HDV, were identified. These results
181 were linked to the reported answers given by each subject in relation to their knowledge on
182 modes of transmission and prevention of HBV, their attitude towards prevention of HBV
183 infection such as vaccination and unprotected sex, as well as their practices that predisposes
184 them to acquiring HBV and/or HDV.

185 All women who tested positive for HBsAg were offered post-test counselling on their status,
186 modes of hepatitis B transmission, need for testing of close contacts for hepatitis B, and
187 vaccination of baby within the first twenty four hours of life against hepatitis B. They were then

PLOS ONE

188 referred for clinical evaluation and management to a gastroenterologist, and those who were
189 negative for HBsAg were advised to get vaccinated if not yet.

190 Statistical analysis

191 Data collected was regularly checked, corrected, recorded and processed using IBM.SPSS.
192 Statistics.v20 software, while ensuring anonymity with the use of subject registration code.
193 Frequencies of qualitative data were estimated as means. Using internal negative and positive
194 controls in each run, a cycle threshold (Ct) of ≤ 35 was considered positive, and $Ct > 35$ and \leq
195 45 was considered a non-quantifiable positive result. Using a standard curve drawn from
196 standards provided by the manufacturer, the HDV RNA load was extrapolated to copies/mL
197 which was then multiplied by a factor (0.18) to convert into IU/mL. The analysis of the
198 relationship between the prevalence and the different characteristics of the sample was done
199 by logistic regression. Using the Pearson Chi-2 test, the factors associated with HBV and
200 HDV infection, were determined with p values < 0.05 considered statistically significant. Ten
201 samples with missing data were not included in the analysis.

202 Ethical considerations

203 The study was conducted in accordance with the fundamental principles of the Declaration of
204 Helsinki, with administrative and ethical approval from health facilities and laboratories, as
205 well as the National Ethics Committee for Human Health Research in Cameroon (N^o
206 2018/06/1150/L/CNERSH/SP), respectively. A written informed consent was obtained from all
207 participants, data was recorded using unique identifiers to ensure confidentiality, and laboratory
208 results were returned to participants for potential benefits in their clinical management. The
209 subjects positive for HBsAg antigen were referred to a gastroenterologist and those HBsAg-
210 negative were advised to be vaccinated if not yet.

211 Results

212 Socio-demographic parameters and Knowledge, Attitude and Practices of pregnant 213 women

214 Overall, 1992 pregnant women were tested for HBsAg, with a mean age of 27.53 ± 5.68 years.
215 The average gestational age was 17 ± 6 weeks, with a majority of the women at the second
216 trimester pregnancy. One thousand nine hundred and thirteen (1913) women have never
217 received the hepatitis B vaccine, but 56 had received three doses of the vaccine (2.8%) (Table
218 1). One thousand six hundred and twenty seven (1627) women were screened for the first time

PLOS ONE

219 for HBsAg during this study (81.7%). In the group of HBsAg-positive women, 53(39.9%)
220 women were in their first pregnancy, 75 (56.4%) lived with a partner, 37 (27.8%) knew their
221 partner's hepatitis B status and 5.4% (2/37) of their partners were positive for HBsAg, 15
222 (11.3%) had already been tattooed or scarified and 21 (15.7%) had a history of surgery.

223 **Prevalence of HDV and HBV Infection markers**

224 Of 1992 pregnant women tested for HBsAg, 133 were positive (6.7%) while 9.8% of women
225 in the third trimester were HBsAg-positive, and 9.9% of them live in the rural area. Of these,
226 42 samples were positive for anti-HDV antibodies by serology, with 62.5% with detectable
227 plasma HDV RNA. Meanwhile, rates of 9.0%, 79.7% and 94.0% for HBeAg, anti-HBe and
228 anti-HBc, respectively, was recorded for the HBsAg-positive specimens. Table 2 shows the
229 distribution of serological markers of hepatitis B infection (HBeAg, HBeAb and HBcAb) as a
230 function of the presence of anti-HDV antibodies, indicating that HBeAg was statistically
231 significantly associated with the presence of anti-HDV antibodies ($p = 0.008$). Two (4.8%)
232 women were co-infected with HCV, HBV and HDV, and 5 (11.9%) with HIV, HBV and HDV.
233 However, HBV/HIV and HBV/HCV co-infections were not associated with anti-HDV
234 positivity in this study. In univariate analysis, neither of HIV nor HCV serologic positivity was
235 associated statistically significantly with the presence of anti-HDV antibodies (Table 2).

236 **Factors associated with hepatitis delta virus infection**

237
238 Our study shows that 4 women with more than 5 children were positive for anti-HDV
239 antibodies. In addition, women living with a partner (44.0%) were more exposed than women
240 living alone (16.4%) to be infected with HDV ($p=0.001$), while 60.0% of women who had been
241 tattooed or scarified had anti-HDV antibodies ($p=0.015$) (Table 3). Comparing the
242 seroprevalence of HDV antibodies against biomarkers of HBV infection, there was a
243 statistically significant difference with the presence of anti-HBc ($p=0.008$), anti-HBe ($p=0.001$)
244 and HBeAg-negative/Anti-HBe+ ($p=0.005$). Of note, the HBeAg-negative/anti-HBe-positive
245 profile was the most frequently detected amongst those with plasma HDV RNA viral load of
246 more than log 3.25 (10.000 copies/mL) (Table 4).

247

248 **Discussion**

249 We studied the seroprevalence of anti-HDV antibodies and the presence of plasma HDV RNA
250 in 130 HBsAg-positive samples, detected in a sample of 1992 pregnant women collected
251 between January 2019 and July 2022 in seven health structures in the Centre Region of

PLOS ONE

252 Cameroon. Overall, we observed a seroprevalence of HBsAg of 6.7%. These results are close
253 to those obtained by Torimiro et al in 2018 (6.4%) among pregnant women in Yaoundé,
254 Cameroon [9]. In comparison to other African countries with similar socio-economic and public
255 health contexts, such as Nigeria, Gabon and Burkina Faso, similar prevalence has been reported
256 [23, 24]. We also noted that in our study population the prevalence of HBsAg is higher among
257 pregnant women in rural areas compared to those in urban areas. Other studies conducted in
258 rural areas in Cameroon, have recorded higher prevalence ranging from 7.5% to 13.7% [25-
259 27].

260 This moderate to high prevalence of hepatitis B in rural areas in Cameroon could be related to
261 the low level of knowledge about hepatitis B modes of transmission and prevention, and risk
262 factors of attitude and practices including idleness and promiscuity. In other words, these are
263 factors that would favour transmission of HDV. Although the efficacy of the hepatitis B vaccine
264 has been proven and has been available since 2005 in the Cameroon EPI [28], this study shows
265 that vaccination coverage remains very low among women of child-bearing age, which
266 contributes in keeping the pool of index infected sub population on the increase. It is therefore
267 not unusual to detect the high prevalence of HDV infection in pregnant women in the Centre
268 Region of Cameroon. Since 1991 when the first study on the prevalence of HDV was conducted
269 in Cameroon[29], several studies have been carried out in the general population or among
270 people with particular socio-demographic characteristics such as pygmies. The variations in the
271 prevalence of anti-HDV antibody ranged from 10.5% to 69% [16, 21, 30-32]. On the other
272 hand, very few of these studies have focused on pregnant women who are an index for both
273 horizontal and vertical transmission of HBV and HDV. These studies reported low levels of
274 anti-HDV antibodies in pregnant women of 2.3-4.0% [9, 29]. These values are low compared
275 to the rate of 32.3% anti-HDV antibody prevalence which we obtained in our study. This
276 difference could be due to the fact that the previous studies were conducted in the Yaoundé an
277 urban area, where there are better living conditions, higher level of education, awareness and
278 knowledge of hepatitis B compared to the semi-urban and rural areas that were included in our
279 study. In comparison of anti-HDV antibody rates among pregnant women in other African
280 countries such as Benin (11.4%), Mauritania (14.7%), Gabon (15.6%), the Central African
281 Republic (21.4%)[33-36], our result is higher at 32.3%.

282 Our findings show that the number of children, marital status, presence of tattoos or
283 scarifications and history of surgery are factors associated with the positivity of anti-HDV

PLOS ONE

284 antibodies. Besombes and colleagues reported in 2020 that individuals with more than 10 sexual
285 casual partners and those who received injections were most at risk of getting HDV [16].

286 The rates of HBV serological markers in anti-HDV-positive individuals showed that anti-HBc
287 antibodies and anti-HBe antibodies were statistically associated with anti-HDV positivity in
288 this study. Similarly, a majority of women with the HBeAg-negative/HBeAb-positive
289 serological profile, had plasma HDV RNA viral load ranging from 10000 to 35000 copies/mL.

290 Limitations of this study include the performance of the test HDV antibody test kit and the lack
291 of a national testing algorithm for diagnosis of HDV infection in Cameroon.

292 **Conclusion**

293 In conclusion, the results of this study show that in spite of the availability of the hepatitis B
294 vaccine in the EPI in Cameroon, HBV infection is moderately endemic (6.7%) in the Centre
295 Region of Cameroon, while HDV rate is 32.3% among pregnant women. Increasing number of
296 casual sexual partners and high level of HDV viremia, may favour horizontal and vertical co-
297 transmission of HDV in this population. Hence, the need to intensify awareness and control
298 strategies for hepatitis B and D among pregnant women and contribute to the global elimination
299 of hepatitis B.

300 **Acknowledgement**

301 We acknowledge the financial and technical contributions from the Chantal Biya International
302 Reference Centre for Research on Prevention and Management of HIV/AIDS to carry out this
303 study.

304 **Funding** was provided by the Chantal Biya International Reference Centre for Research on
305 Prevention and Management of HIV/AIDS (CIRCB). And the WHO Sasakawa 2019 Health
306 Prize to Judith Torimiro.

307

308 **References**

- 309 1. WHO, Key facts on hepatitis B. 2020.
- 310 2. Sawadogo, A., et al., *Seroprevalence of hepatitis D virus infection in a population of*
311 *blood donors carrying HBs Antigen at the Bobo-Dioulasso Regional Blood Transfusion*
312 *Center*. Journal Africain d'Hépatogastroentérologie, 2016. **10**(1): p. 31-33.

PLOS ONE

- 313 3. Sahin, A., et al., *Anti-HDV seroprevalance among patients with previous HBV infection.*
314 North Clin Istanb, 2018. **5**(2): p. 132-138.
- 315 4. Medhat, A., et al., *Acute viral hepatitis in pregnancy.* Int J Gynaecol Obstet, 1993.
316 **40**(1): p. 25-31.
- 317 5. Dulger, A.C., et al., *High prevalence of chronic hepatitis D virus infection in Eastern*
318 *Turkey: urbanization of the disease.* Arch Med Sci, 2016. **12**(2): p. 415-20.
- 319 6. A.T. Kabamba, C.M.M., C.M. Nyembo, B.M. Kabamba Et And A.O. Longanga,
320 *Hepatitis D seroprevalence among people with chronic hepatitis B in Lubumbashi*
321 *(DRC).* 2020.
- 322 7. Stockdale, A.J., et al., *Prevalence of hepatitis D virus infection in sub-Saharan Africa:*
323 *a systematic review and meta-analysis.* Lancet Glob Health, 2017. **5**(10): p. e992-e1003.
- 324 8. Daw, M.A., et al., *The Epidemiology of Hepatitis D Virus in North Africa: A Systematic*
325 *Review and Meta-Analysis.* ScientificWorldJournal, 2018. **2018**: p. 9312650.
- 326 9. Torimiro, J.N., et al., *Rates of HBV, HCV, HDV and HIV type 1 among pregnant women*
327 *and HIV type 1 drug resistance-associated mutations in breastfeeding women on*
328 *antiretroviral therapy.* BMC Pregnancy Childbirth, 2018. **18**(1): p. 504.
- 329 10. WHO, *Key facts on hepatitis D.* 2022.
- 330 11. Zanetti, A.R., et al., *Perinatal transmission of the hepatitis B virus and of the HBV-*
331 *associated delta agent from mothers to offspring in northern Italy.* J Med Virol, 1982.
332 **9**(2): p. 139-48.
- 333 12. Huang, Y.H., et al., *Phylogenetic analysis to document a common source of hepatitis D*
334 *virus infection in a mother and her child.* Zhonghua Yi Xue Za Zhi (Taipei), 1999.
335 **62**(1): p. 28-32.
- 336 13. Sellier, P., et al., *Untreated highly viraemic pregnant women from Asia or sub-Saharan*
337 *Africa often transmit hepatitis B virus despite serovaccination to newborns.* Liver Int,
338 2015. **35**(2): p. 409-16.
- 339 14. Sellier, P.O., et al., *Hepatitis B Virus-Hepatitis D Virus mother-to-child co-*
340 *transmission: A retrospective study in a developed country.* Liver Int, 2018. **38**(4): p.
341 611-618.
- 342 15. Yuan, J., et al., *Antepartum immunoprophylaxis of three doses of hepatitis B*
343 *immunoglobulin is not effective: a single-centre randomized study.* J Viral Hepat, 2006.
344 **13**(9): p. 597-604.
- 345 16. Besombes, C., et al., *The epidemiology of hepatitis delta virus infection in Cameroon.*
346 Gut, 2020. **69**(7): p. 1294-1300.

PLOS ONE

- 347 17. Stockdale, A.J., et al., *The global prevalence of hepatitis D virus infection: Systematic*
348 *review and meta-analysis*. J Hepatol, 2020. **73**(3): p. 523-532.
- 349 18. Bigna, J.J., et al., *Seroprevalence of hepatitis B virus infection in Cameroon: a*
350 *systematic review and meta-analysis*. BMJ Open, 2017. **7**(6): p. e015298.
- 351 19. CAMPHIA 2017 population impact assessment of HIV in Cameroon,. 2020.
- 352 20. Directorate for Disease Control, the E.e.I.P.-D., *Monitoring Report on Key Health*
353 *Indicators in Cameroon in 2019*. 2022.
- 354 21. Butler, E.K., et al., *High prevalence of hepatitis delta virus in Cameroon*. Sci Rep, 2018.
355 **8**(1): p. 11617.
- 356 22. Pourhoseingholi, M.A., M. Vahedi, and M. Rahimzadeh, *Sample size calculation in*
357 *medical studies*. Gastroenterol Hepatol Bed Bench, 2013. **6**(1): p. 14-7.
- 358 23. Groc, S., et al., *High prevalence and diversity of hepatitis B and hepatitis delta virus in*
359 *Gabon*. J Viral Hepat, 2019. **26**(1): p. 170-182.
- 360 24. Lingani, M., et al., *The changing epidemiology of hepatitis B and C infections in*
361 *Nanoro, rural Burkina Faso: a random sampling survey*. BMC Infect Dis, 2020. **20**(1):
362 p. 46.
- 363 25. Sone, L.H.E., et al., *Prevalence and Identification of Serum Markers Associated with*
364 *Vertical Transmission of Hepatitis B in Pregnant Women in Yaounde, Cameroon*. Int J
365 MCH AIDS, 2017. **6**(1): p. 69-74.
- 366 26. Eyong, E.M., et al., *The prevalence of HBsAg, knowledge and practice of hepatitis B*
367 *prevention among pregnant women in the Limbe and Muyuka Health Districts of the*
368 *South West region of Cameroon: a three-year retrospective study*. Pan Afr Med J, 2019.
369 **32**: p. 122.
- 370 27. Mawouma, A.R.N., et al., *[Factors associated with hepatitis B infection in pregnant*
371 *women at health facilities in the health district of Mokolo/Far North of Cameroon]*. Pan
372 Afr Med J, 2022. **41**: p. 61.
- 373 28. Gatchalian, S., et al., *A new DTPw-HBV/Hib vaccine is immunogenic and safe when*
374 *administered according to the EPI (Expanded Programme for Immunization) schedule*
375 *and following hepatitis B vaccination at birth*. Hum Vaccin, 2005. **1**(5): p. 198-203.
- 376 29. Ndumbe, P.M., *Hepatitis D in Yaounde, Cameroon*. Apmis, 1991. **99**(2): p. 196-8.
- 377 30. Noubissi-Jouegouo, L., et al., *Evolutionary trends in the prevalence of anti-HDV*
378 *antibodies among patients positive for HBsAg referred to a national laboratory in*
379 *Cameroon from 2012 to 2017*. BMC Res Notes, 2019. **12**(1): p. 417.

PLOS ONE

- 380 31. Luma, H.N., et al., *Prevalence and Characteristics of Hepatitis Delta Virus Infection in*
381 *a Tertiary Hospital Setting in Cameroon*. J Clin Exp Hepatol, 2017. **7**(4): p. 334-339.
- 382 32. Foupouapouognigni, Y., et al., *Endemicity and genetic diversity of Hepatitis delta virus*
383 *among Pygmies in Cameroon, Central Africa*. BMC Res Notes, 2022. **15**(1): p. 87.
- 384 33. Mansour, W., et al., *Prevalence, risk factors, and molecular epidemiology of hepatitis*
385 *B and hepatitis delta virus in pregnant women and in patients in Mauritania*. J Med
386 Virol, 2012. **84**(8): p. 1186-98.
- 387 34. Makuwa, M., et al., *Prevalence and genetic diversity of hepatitis B and delta viruses in*
388 *pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8*
389 *originates from and is endemic in central Africa*. J Clin Microbiol, 2008. **46**(2): p. 754-
390 6.
- 391 35. Komas, N.P., et al., *Hepatitis B and hepatitis D virus infections in the Central African*
392 *Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing*
393 *spread in asymptomatic young adults*. PLoS Negl Trop Dis, 2018. **12**(4): p. e0006377.
- 394 36. De Paschale, M., et al., *Prevalence of HBV, HDV, HCV, and HIV infection during*
395 *pregnancy in northern Benin*. J Med Virol, 2014. **86**(8): p. 1281-7.

396

PLOS ONE

397 **Table 1: Characteristics of the study population**

Variables		HBsAg		p-value
		Negative (%)	Positive (%)	
Age (years) Mean = 27 years	15-20	209 (91.2)	19 (8.8)	0,21
	21-25	580 (92.2)	49 (7.8)	
	26-30	507 (94.9)	27 (5.1)	
	31-35	360 (93.0)	27 (7.0)	
	36-40	172 (94.0)	11 (6.0)	
	41-45	31 (100.0)	0 (0)	
Gestational age (weeks) Mean = 18 weeks	1-14	527(92.1)	45(7.9)	0 .017*
	15-28	940(94.4)	65(5.6)	
	29-42	374(90.1)	41(9.9)	
Hepatitis B vaccination	Not vaccinated	1779(93.04%)	133(7.0)	0.637
	1 Dose	10(100.0%)	0(0)	
	2 Doses	14(100.0%)	0(0)	
	3 Doses	56(0.58%)	0(0)	
Location of health institution/study site	urban	1169(94.88%)	63(5.1)	0 .016*
	semi-urban	263(91.96%)	23(8.0)	
	rural	427(90.08%)	47(9.9)	

398

399 **.The Chi-square statistic is significant at the .05 level.*

400

401

PLOS ONE

402 **Table 2: Distribution of viral infections (HCV, HDV, and HIV) and serological markers**
 403 **of hepatitis B infection among HBsAg-positive pregnant women**

Serological markers		Presence of anti-HDV antibodies		
		Negative (%)	Positive (%)	P-value
Anti-HIV	Negative	80(68.4)	37(31.6)	0.612
	Positive	8(61.5)	5(38.46)	
Anti-HCV	Negative	88(68.8)	40(31.2)	0.119
	Positive	0(0)	2(100.0)	
HBeAg	Negative	82(69.5)	36(30.5)	0.169
	Positive	6(50.0)	6(50.0)	
HBc antibodies	Negative	2(25.0)	6(75.0)	0.008*
	Positive	86(70.5)	36(29.5)	
HBe antibodies	Negative	9(36.0)	16(64.0)	0.001*
	Positive	79(75.2)	26(24.8)	
HBeAg-/HBeAb -		8(44.4)	10(55.6)	0.005*
HBeAg+/HBeAb -		0(0)	6(100.0)	
HBeAg-/HBeAb +		75(75.3)	26(25.7)	
HBeAg+/HBeAb +		5(100.0)	0(0)	

404

405 *Note*

406 **+**: positive;

407 **-**: negative;

408 **.The Chi-square statistic is significant at the .05 level.*

409

PLOS ONE

410 **Table 3: Variation in the prevalence of hepatitis delta according to the clinical**
 411 **characteristics of pregnant women**

Variable	Presence of anti-HDV antibodies			
	Negative (%)	Positive (%)	p-value	
Age Group (years) Mean = 26 years	15-20	16(84.2)	3 (15.8)	0.50
	21-25	31 (66.0)	16 (34.0)	
	26-30	17 (60.7)	11 (39.3)	
	31-35	18 (69.2)	8 (30.8)	
	36-40	6 (60.0)	4 (40.0)	
Gestational age (weeks) Mean : 22 (weeks)	1-14	18 (69.2)	8 (30.2)	0.92
	15-28	34 (68.0)	16 (32.0)	
	29-42	36 (66.7)	18 (33.3)	
Number of life births	0	40 (75.5)	13 (24.5)	0.030
	1	26 (72.2)	10 (27.8)	
	2	10 (62.5)	6 (37.5)	
	3	11 (55.0)	9 (45.0)	
	4	1 (100.0)	0 (0.0)	
	5+	0 (0.0)	4 (100.0)	
Marital status	life alone	46 (83.6)	9 (16.4)	0.001*
	married life	42 (56.0)	33 (44.0)	
Knowledge of tattoo	yes	6 (40.0)	9 (60.0)	0.015*
	no	82 (71.3)	33 (28.7)	
History of surgical operations	yes	19 (90.5)	2 (9.5)	0.015*
	no	69 (63.3)	40 (36.7)	
Knowledge of female circumcision	yes	5 (100.0)	0 (00.0)	0.115
	no	83 (66.4)	42 (33.6)	
Use of alcohol	yes	39 (68.4)	18 (31.6)	0.87
	no	49 (67.1)	24 (32.9)	
Aware of hepatitis B status of close people	no one knows	2 (100.0)	0 (00.0)	0.189
	husband	15 (60.0)	10 (40.0)	
	family member	0 (00.0)	2 (100.0)	
	friend	46 (64.8)	25 (35.2)	

412

413 *Note*

414 **.The Chi-square statistic is significant at the .05 level.*

415

PLOS ONE

416 **Table 4: Plasma HDV RNA viral load as a function of the serological profile of HBeAb**
417 **and HBeAg markers**

Serological profile	HDV RNA viral load (copies/mL)				
	Not detected	< 15	(15-1000)	(1000-10000)	(10000-35000)
HBeAg-/HBeAb -	5(33.33%)	0(0.0%)	2(40.0%)	2(40.0%)	0(0.0%)
HBeAg+/HBeAb -	1(6.67%)	0(0.0%)	1(20.0%)	0(0.0%)	1(20.0%)
HBeAg-/HBeAb +	9(60.0%)	4(100.0%)	2(40.0%)	3(60.0%)	4(80.0%)
Total	15	4	5	5	5

418




Figure 2: Diagram showing procedure of screening for HBsAg and antibodies to and RNA of HDV of pregnant women.

Figure 2